8OZ3
Crystal structure of scFv ATOR 1017 bound to human 4-1BB
Summary for 8OZ3
| Entry DOI | 10.2210/pdb8oz3/pdb |
| Descriptor | Single chain Fv, Tumor necrosis factor receptor superfamily member 9, ... (4 entities in total) |
| Functional Keywords | complex, single chain fv, tumor necrosis factor, immune system |
| Biological source | Homo sapiens More |
| Total number of polymer chains | 6 |
| Total formula weight | 126341.00 |
| Authors | Hakansson, M.,Von Schantz, L.,Rose, N. (deposition date: 2023-05-08, release date: 2024-03-13, Last modification date: 2024-11-06) |
| Primary citation | Enell Smith, K.,Fritzell, S.,Nilsson, A.,Barchan, K.,Rosen, A.,Schultz, L.,Varas, L.,Sall, A.,Rose, N.,Hakansson, M.,von Schantz, L.,Ellmark, P. ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1. Cancer Immunol.Immunother., 72:4145-4159, 2023 Cited by PubMed Abstract: 4-1BB (CD137) is a co-stimulatory receptor highly expressed on tumor reactive effector T cells and NK cells, which upon stimulation prolongs persistence of tumor reactive effector T and NK cells within the tumor and induces long-lived memory T cells. 4-1BB agonistic antibodies have been shown to induce strong anti-tumor effects that synergize with immune checkpoint inhibitors. The first generation of 4-1BB agonists was, however, hampered by dose-limiting toxicities resulting in suboptimal dose levels or poor agonistic activity. PubMed: 37796298DOI: 10.1007/s00262-023-03548-7 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (3.1 Å) |
Structure validation
Download full validation report
